Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma.
Bortezomib, a reversible proteasome inhibitor, is used for the treatment of hematologic malignancies. Common adverse events with bortezomib include gastrointestinal symptoms, thrombocytopenia, and neuropathy, whereas severe pulmonary complications have been rarely described. Herein, we present a case of rapid fatal pulmonary complications in a patient with ALK-negative anaplastic large-cell lymphoma after receiving a treatment with bortezomib.
Zhou
Xin
X
Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China.
Sun
Chao
C
Wang
Jing
J
Mao
Jingjue
J
Guo
Hongfeng
H
D000368:Aged; D044466:Asian People; D001897:Boronic Acids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000069286:Bortezomib; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D017809:Fatal Outcome; D019337:Hematologic Neoplasms / Q000139:chemically induced / Q000201:enzymology; D006801:Humans; D008168:Lung / Q000201:enzymology / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced / Q000188:drug therapy / Q000201:enzymology; D017728:Lymphoma, Large-Cell, Anaplastic / Q000139:chemically induced / Q000201:enzymology; D008297:Male; D011719:Pyrazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D001897:Boronic Acids; D004791:Enzyme Inhibitors; D011719:Pyrazines; D000069286:Bortezomib